mainPic
About Us
- organization

Board of Directors

Jeffrey Suen : Chairman, Legal Representative of TTY Biopharm Co., Ltd

Mr. Suen is the advisor of TTY Biopharm Co., Ltd. and was previously the General Manager of China Development Industrial Bank, the largest VC for biotech. He received his MBA at Young America City State University in US.

Grace Yeh, Ph.D. : Founder, President & Chief Executive Officer

Dr. Yeh worked in academic research in England and France, as well as in drug discovery and development at T Cell Sciences, CytoMed, LeukoSite, and Millennium Pharmaceuticals in Cambridge, MA, USA. She received her Ph.D. in Immunology at the Medical University of South Carolina, Charleston, SC, USA. She is a successful advocate in building and leading multi-disciplinary teams and in creating development strategies and resource plans to allow accelerated regulatory approval. Over the past thirteen years, under her leadership PharmaEngine has achieved many important milestones, including FDA approval of its new drug, ONIVYDE.

Wen-hwa Chang : Legal Representative of TTY Biopharm Co., Ltd.

Mrs. Chang is now vice chairman of TTY Biopharm Co., Ltd.

Ming-thau Sheu: Legal Representative of TTY Biopharm Co., Ltd.

Mr. Sheu is Professor in the Department of Pharmacy, Taipei Medical University, and was previously the Dean in the Department of Pharmacy. He received his Ph.D. in Pharmacology at Ohio State University, USA.

Li-Chen Lin : Legal Representative of the National Development Fund, Executive Yuan

Mrs. Lin is the Associate Director of the National Development Council and was previously the Chief Secretary of the Council for Economic Planning and Development, Executive Yuan. She received her master in Economics at National Taipei University, Taipei, Taiwan.

Gour-Tsair Pan
Legal Representative of the National Development Fund, Executive Yuan

Mr. Pan is a Master of Department of Surveying Engineering, National Cheng Kung University (NCKU). Mr. Pan has served as Assistant Research fellow of National Science Council of Executive Yuan, Research fellow of Council for Economic Planning and Development of Executive Yuan, and Director of Information Management Department of Council of Agriculture of Executive Yuan. At present he serves as Director of Information Management Department of National Development Council.

Fu-Shiow Yin, Ph.D. : Independent Director

Dr. Yin is an Independent Director of Pac-Link BioVenturesShe has been on the evaluation committee for biomedical projects in the government department(MOEA) for many years. She earned her Ph.D. in Biochemistry at Rutgers University, New Jersey, USA.

Frank Li-Sheng Chu : Independent Director

Mr. Chu is Vice General Manager of the Industry Academia Collaboration Office at Asia University, Taiwan. He is also an Independent Director for Wellpool Co., Ltd., and Yue Yuen Industrial (Holdings) Ltd. He received his master in Business Administration at National Taiwan University.

Kang-chi Chou: Independent Director

Mr. Chou is the vice chairman and general manager of iROC Ltd. and was previously the chairman of Concord Securities Group. He received his MBA at University of St. Thomas in US.

Management team

Jeffrey Suen: Chairman

Mr. Suen is the advisor of TTY Biopharm Co., Ltd. and was previously the General Manager of China Development Industrial Bank, the largest VC for biotech. He received his MBA at Young America City State University in US.

Dr. Grace Yeh, Ph.D. : Founder, President & Chief Executive Officer

Dr. Yeh founded PharmaEngine, Inc. in Jan. 2003, and has served as President and Chief Executive Officer. She worked in academic research institutions in England and France, as well as in drug discovery and development at T Cell Sciences, CytoMed, LeukoSite, and Millennium Pharmaceuticals in Cambridge, MA, USA. She has been successful in building and leading multi-disciplinary teams and in creating development strategies and resource plans to allow accelerated regulatory approval. She received her Ph.D. in Immunology at the Medical University of South Carolina, Charleston, SC, USA.

Dr. Alain Herrera, M.D. : Head, Corporate Development; Managing Director, PharmaEngine Europe Sarl

Dr. Herrera joined the Scientific Advisory Board of PharmaEngine in November 2008. He created the Foundation of Alain Oncology Consulting in November 2008 after heading for ten years the oncology business at sanofi-aventis where he was successively Vice President responsible for Global Oncology Business Strategy and Development (2007-2008) and Head of Global Oncology Franchise (1998-2007) and contributed to the worldwide registration of two products: oxaliplatin (ELOXATIN®) and rasburicase (FASTURTEC®/ELITEK®) as well as the gastric and head & neck indications for docetaxel (TAXOTERE®). He received his MD from Pitié-Salpétrière Hospital, Faculty of Medicine, Paris, France.

Dr. C. Hubert Chan, MD, Ph.D. : Vice President, Clinical and Regulatory Affairs

Dr. Chan joined PharmaEngine in February 2016. He is a board certified medical oncologist. In addition to clinical practice, he has involved in several global clinical trials. He conducted two investigator initiated trials while he was at National Health Research Institutes, Taiwan. His expertise will facilitate the success of clinical research, which is essential for the new drug development. He received his Ph.D. at University of Minnesota, USA and MD at Chung Shan Medical University, Taiwan.

Dr. Armand de Gramont Ph.D. : Vice President, Translational Science

Dr. de Gramont joined the Scientific Advisory Board since January 2012. He was trained at the Laboratory of Molecular and Cellular Biology, National Institutes of Health (NIH), USA. After returning to France, he became Chief Operating Officer & General Manager at AAREC Filia Research, Paris. Most recently, he was Head of the New Drugs Evaluation Laboratory, Lausanne University Hospital, Switzerland. His expertise is in the area of translational medicine in oncology. He received his Ph.D. in Cellular Biochemistry at Pierre et Marie Curie University, Paris, France.

C. H. Chang: Vice President, Finance & Administration

Mr. Chang joined PharmaEngine in February 2003. He is a certified public accountant (CPA) in Taiwan. He worked at TTY Biopharm as the Director of Stock Affairs Department, and MasterLink Securities and Sampo Securities for many years majored in IPOs in Taiwan. He received his Master degree of Accounting from National Taiwan University, Taiwan.

Peter Wu: Senior Director, Marketing & Sales

Mr. Wu joined PharmaEngine in July 2004. He majored in marketing and sales of oncology products at Novartis (Taiwan) and Kirin (Taiwan), responsible for Glivec®, Aredia®, G-CSF and EPO. Mr. Wu received his Bachelor degree in Pharmacy, Taipei Medical University, Taiwan.

TOP